PPARA and neoplasm: Because of the prevalence of positivecarcinogenicity findings with PPAR agonists and the lack of completeunderstanding of PPAR-induced tumor development, 2-year carcinogenicity studiesin mice and rats are now required before clinical trials longer than 6 monthsin duration can be initiated [93, 94].